Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation

由 McWhirter, John R., Kretz-Rommel, Anke, Saven, Alan, Maruyama, Toshiaki, Potter, Kathleen N., Mockridge, C. Ian, Ravey, E. Prenn, Qin, Fenghua, Bowdish, Katherine S.
出版 2006

FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion

由 Oldham, Robert J, Mockridge, C Ian, James, Sonya, Duriez, Patrick J, Chan, H T Claude, Cox, Kerry L, Pitic, Vicentiu A, Glennie, Martin J, Cragg, Mark S
發表在 J Immunother Cancer (2020)

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking

由 Turaj, Anna H., Cox, Kerry L., Penfold, Christine A., French, Ruth R., Mockridge, C. Ian, Willoughby, Jane E., Tutt, Alison L., Griffiths, Jordana, Johnson, Peter W. M., Glennie, Martin J., Levy, Ronald, Cragg, Mark S., Lim, Sean H.
發表在 Sci Rep (2018)

Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity

由 Yu, Xiaojie, Chan, H.T. Claude, Fisher, Hayden, Penfold, Christine A., Kim, Jinny, Inzhelevskaya, Tatyana, Mockridge, C. Ian, French, Ruth R., Duriez, Patrick J., Douglas, Leon R., English, Vikki, Verbeek, J. Sjef, White, Ann L., Tews, Ivo, Glennie, Martin J., Cragg, Mark S.
發表在 Cancer Cell (2020)

TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity

由 Yu, Xiaojie, James, Sonya, Felce, James H., Kellermayer, Blanka, Johnston, David A., Chan, H. T. Claude, Penfold, Christine A., Kim, Jinny, Inzhelevskaya, Tatyana, Mockridge, C. Ian, Watanabe, Yasunori, Crispin, Max, French, Ruth R., Duriez, Patrick J., Douglas, Leon R., Glennie, Martin J., Cragg, Mark S.
發表在 Commun Biol (2021)

Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies

由 Yu, Xiaojie, Chan, H.T. Claude, Orr, Christian M., Dadas, Osman, Booth, Steven G., Dahal, Lekh N., Penfold, Christine A., O'Brien, Lyn, Mockridge, C. Ian, French, Ruth R., Duriez, Patrick, Douglas, Leon R., Pearson, Arwen R., Cragg, Mark S., Tews, Ivo, Glennie, Martin J., White, Ann L.
發表在 Cancer Cell (2018)

LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation

由 Yeboah, Muchaala, Papagregoriou, Charys, Jones, Des C., Chan, H.T. Claude, Hu, Guangan, McPartlan, Justine S., Schiött, Torbjörn, Mattson, Ulrika, Mockridge, C. Ian, Tornberg, Ulla-Carin, Hambe, Björn, Ljungars, Anne, Mattsson, Mikael, Tews, Ivo, Glennie, Martin J., Thirdborough, Stephen M., Trowsdale, John, Frendeus, Björn, Chen, Jianzhu, Cragg, Mark S., Roghanian, Ali
發表在 JCI Insight (2020)

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

由 White, Ann L., Chan, H.T. Claude, French, Ruth R., Willoughby, Jane, Mockridge, C. Ian, Roghanian, Ali, Penfold, Christine A., Booth, Steven G., Dodhy, Ali, Polak, Marta E., Potter, Elizabeth A., Ardern-Jones, Michael R., Verbeek, J. Sjef, Johnson, Peter W.M., Al-Shamkhani, Aymen, Cragg, Mark S., Beers, Stephen A., Glennie, Martin J.
發表在 Cancer Cell (2015)

Domain binding and isotype dictate the activity of anti-human OX40 antibodies

由 Griffiths, Jordana, Hussain, Khiyam, Smith, Hannah L, Sanders, Theodore, Cox, Kerry L, Semmrich, Monika, Mårtensson, Linda, Kim, Jinny, Inzhelevskaya, Tatyana, Penfold, Chris A, Tutt, Alison L, Mockridge, C Ian, Chan, HT Claude, English, Vikki, French, Ruth F, Teige, Ingrid, Al-Shamkhani, Aymen, Glennie, Martin J, Frendeus, Bjorn L, Willoughby, Jane E, Cragg, Mark S
發表在 J Immunother Cancer (2020)